Author
@adamfeuerstein adamfeuerstein
grade Ax.com/adamfeuerstein ↗
Veteran biotech journalist decoding clinical data and calling out hype
Breaks biotech/pharma news and delivers skeptical, data-lite
trader score
+1.41
hit rate
35%
mean α
+6.22%
signals 14d
74
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 35% hit rate, +6.22% mean alpha, trader score +1.41. Their last-14d mentions, direction-adjusted, have moved -5.3% since posting (mean over 37 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | CYTK | @adamfeuerstein | +0.50 | Cytokinetics reported a successful trial that could support its next regulatory approval. | — | tweet ↗ |
| 2026-08-28 | · | @adamfeuerstein | · | The author endorses shorting around clear catalysts, but no security or specific trade is identified. | · | tweet ↗ |
| 2026-08-28 | · | @adamfeuerstein | · | Warns that valuation-based short positions are difficult, without identifying a security. | · | tweet ↗ |
| 2026-08-28 | ALNY | @adamfeuerstein | -0.65 | Reports adverse CARDIO-TTRansform combination-arm data and negative interpretations from three sell-side analysts. | — | tweet ↗ |
| 2026-08-28 | IONS | @adamfeuerstein | -0.25 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | · | tweet ↗ |
| 2026-08-28 | ALNY | @adamfeuerstein | -0.35 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | — | tweet ↗ |
| 2026-08-28 | BBIO | @adamfeuerstein | +0.18 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | — | tweet ↗ |
| 2026-08-28 | AZN | @adamfeuerstein | -0.25 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | — | tweet ↗ |
| 2026-08-28 | IONS | @adamfeuerstein | -0.35 | Reports a failed AstraZeneca heart-disease study and broader concerns for silencer drugs. | · | tweet ↗ |
| 2026-08-28 | ALNY | @adamfeuerstein | -0.35 | Reports a failed AstraZeneca heart-disease study and broader concerns for silencer drugs. | — | tweet ↗ |
| 2026-08-28 | AZN | @adamfeuerstein | -0.60 | Reports a failed AstraZeneca heart-disease study and broader concerns for silencer drugs. | — | tweet ↗ |
| 2026-08-27 | ROIV | @adamfeuerstein | +0.50 | FDA approved Roivant's Lisraya therapy for a rare autoimmune disease. | · | tweet ↗ |
| 2026-08-27 | ALNY | @adamfeuerstein | -0.45 | Highlights adverse read-through for Alnylam from a failed heart-drug study. | +0.2% | tweet ↗ |
| 2026-08-27 | MRNA | @adamfeuerstein | +0.20 | Suggests shorts may be frustrated that Moderna chose convertible debt instead of discounted equity. | -3.3% | tweet ↗ |
| 2026-08-27 | MRNA | @adamfeuerstein | -0.20 | Reports Moderna's $2 billion convertible senior-note offering. | -3.3% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.